Halozyme Therapeutics (HALO) earnings

Earnings (net income) · fiscal 2025
$316.89M

Halozyme Therapeutics (HALO) reported net income of $316.89M in fiscal 2025 (the year ended December 31, 2025). That is 28.6% lower than the $444.09M of fiscal 2024. Figures as of 18 Nov 2026, 07:01 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Earnings (net income), fiscal 2025
$316.89M
Change on fiscal 2024
−28.6%
Growth, 5 years
+19.7% a year
Highest on record
$444.09Mfiscal 2024
Lowest on record
-$103.02Mfiscal 2016
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Halozyme Therapeutics earnings, in more detail

Over the five fiscal years to 2025 net income grew at a compound 19.7% a year. Across the 17 fiscal years on record (2009–2025), the highest was $444.09M in fiscal 2024 and the lowest -$103.02M in fiscal 2016.

History · 17 fiscal years

Earnings (net income) by fiscal year

Halozyme Therapeutics earnings, year by year

Halozyme Therapeutics (HALO) earnings by fiscal year
Fiscal yearEarnings (net income)ChangeYear ended
2025$316.89M 28.6% down
2024$444.09M 57.7% up
2023$281.59M 39.3% up
2022$202.13M 49.8% down
2021$402.71M 212.0% up
2020$129.09M—
2019-$72.24M—
2018-$80.33M 227.6% down
2017$62.97M—
2016-$103.02M—
2015-$32.23M—
2014-$68.38M—
2013-$83.48M—
2012-$53.55M—
2011-$19.77M—
2010-$53.24M—
2009-$58.36M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

How to read it

Compare it across years rather than in isolation — one-off gains and write-downs can swing a single year a long way.

Earnings (net income) at health care companies of similar size

Earnings (net income) of Halozyme Therapeutics and comparable companies
CompanyEarnings (net income)Fiscal year
Fresenius Medical Care FMS€978.37M2025
Kymera Therapeutics KYMR-$311.35M2025
DaVita DVA$746.80M2025
Halozyme Therapeutics HALO$316.89M2025
Universal Health Services UHS$1.49B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HALO

Halozyme Therapeutics, figure by figure

Halozyme Therapeutics (HALO) overview: price, valuation and scorecardAll health care companies by market value

Halozyme Therapeutics earnings: questions and answers

What is Halozyme Therapeutics's net income?

Halozyme Therapeutics (HALO) reported net income of $316.89M in fiscal 2025 (the year ended December 31, 2025). That is 28.6% lower than the $444.09M of fiscal 2024.

What is the growth rate of Halozyme Therapeutics's net income?

Over the five fiscal years to 2025 net income grew at a compound 19.7% a year.

What are the highest and lowest net income figures on record for Halozyme Therapeutics?

Across the 17 fiscal years on record (2009–2025), the highest was $444.09M in fiscal 2024 and the lowest -$103.02M in fiscal 2016.

How is Halozyme Therapeutics's net income calculated?

Earnings here means net income: what is left of the year's revenue after every cost, interest and tax, as reported on the income statement.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Halozyme Therapeutics (HALO) earnings”, data as of 18 November 2026. https://funkfolio.com/stock/HALO/earnings

Underlying data: the company's filings with the SEC and Yahoo Finance.